[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Karyopharm Therapeut (KPTI)

Karyopharm Therapeut (KPTI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,646
  • Shares Outstanding, K 22,663
  • Annual Sales, $ 146,070 K
  • Annual Income, $ -196,040 K
  • EBIT $ -84 M
  • EBITDA $ -74 M
  • 60-Month Beta 0.90
  • Price/Sales 0.30
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 552.55% (+412.26%)
  • Historical Volatility 377.90%
  • IV Percentile 99%
  • IV Rank 98.81%
  • IV High 558.15% on 03/19/26
  • IV Low 87.31% on 04/10/26
  • Expected Move (DTE 17) 0.6375 (31.80%)
  • Put/Call Vol Ratio 0.38
  • Today's Volume 584
  • Volume Avg (30-Day) 2,108
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 45,837
  • Open Int (30-Day) 38,918
  • Expected Range 1.3675 to 2.6425

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.53
  • Number of Estimates 2
  • High Estimate $-1.38
  • Low Estimate $-1.68
  • Prior Year $-4.32
  • Growth Rate Est. (year over year) +64.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.8000 +10.83%
on 08/03/26
10.8600 -81.63%
on 07/08/26
-7.6050 (-79.22%)
since 07/02/26
3-Month
1.8000 +10.83%
on 08/03/26
10.8600 -81.63%
on 07/08/26
-7.3050 (-78.55%)
since 05/04/26
52-Week
1.8000 +10.83%
on 08/03/26
10.9900 -81.85%
on 02/24/26
-2.0250 (-50.37%)
since 08/04/25

Most Recent Stories

More News
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass. , Aug. 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company...

KPTI : 1.9700 (+0.25%)
Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway

– Company Plans to Submit sNDA in August 2026 and Will Request Priority Review –

KPTI : 1.9700 (+0.25%)
Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer

– The Trial Did Not Meet the Primary Endpoint of Progression-Free Survival (PFS) –

KPTI : 1.9700 (+0.25%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

NEW YORK , July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI). Such investors...

KPTI : 1.9700 (+0.25%)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass. , July 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company...

KPTI : 1.9700 (+0.25%)
Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026

NEWTON, Mass. , June 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will...

KPTI : 1.9700 (+0.25%)
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026

– New Data will Highlight a Post-Hoc Analysis from Phase 1 Portion of SENTRY Trial that Indicates Achievement of SVR35 with Selinexor plus Ruxolitinib May Predict Overall Survival –

KPTI : 1.9700 (+0.25%)
Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology

– Selinexor in Combination with Ruxolitinib Demonstrated a Rapid and Near Doubling of Patients Achieving SVR35 at Week 24, versus Ruxolitinib, with a Consistent SVR35 Benefit Observed Across Prespecified...

KPTI : 1.9700 (+0.25%)
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass. , June 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company...

KPTI : 1.9700 (+0.25%)
Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation

– Event To Feature Dr. John Mascarenhas, Principal Investigator of the Phase 3 SENTRY Trial –

KPTI : 1.9700 (+0.25%)

Business Summary

Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States.

See More

Key Turning Points

3rd Resistance Point 2.3300
2nd Resistance Point 2.1900
1st Resistance Point 2.0800
Last Price 1.9700
1st Support Level 1.8300
2nd Support Level 1.6900
3rd Support Level 1.5800

See More

52-Week High 10.9900
Fibonacci 61.8% 7.4794
Fibonacci 50% 6.3950
Fibonacci 38.2% 5.3106
Last Price 1.9700
52-Week Low 1.8000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.